Search Results

1 - 10 of 27 items :

  • "prostate cancer" x
  • Endocrinology, Diabetology x
Clear All
Dynamics of Prostate-Specific Antigen Levels During Treatment with Testosterone Undecanoate in Patients with Type 2 Diabetes Mellitus

References 1. Crawford ED, Abrahamsson PA . PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 54: 262-273, 2008 . 2. Heinlein CA, Chang C . Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004. 3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265, 1996. 4. Velcheti V, Karnik S, Bardot SF, Prakash O . Pathogenesis

Open access
A hypothetical approach on gender differences in cancer diagnosis

dissemination of cancerous cells. Moreover, it was shown that breast cancer patients with no expression of estrogen or progesterone receptors but positive for MMP-2 had worst disease-free and overall survival rates. [ 20 ] On the other hand, androgen as male steroid hormone can stimulate MMP-2 expression in human prostate cancer cells; [ 21 ] and elevated levels of androgen receptors, MMP-2 and MMP-9 in human hepatocellular carcinoma tissues are associated with higher invasive potential of these liver tumors. [ 22 ] Therefore, based on the hypothesis proposed in the

Open access
The bone hormones and their potential effects on glucose and energy metabolism

mice. Diabetes 59, 1376–1385, 2010. Herman W. The global burden of diabetes: An overview. In: Diabetes mellitus in developing countries and under-served communities (Ed. S. Dagogo-Jack), Springer International Publishing, Switzerland, pp. 1–5, 2017. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of Megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 14, 3823–3831, 2008. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the

Open access
Hypoxic regulation of EDN1, EDNRA, EDNRB, and ECE1 gene expressions in ERN1 knockdown U87 glioma cells

and tumor growth. Oncotarget 5, 6670–6686, 2014. Chevet E, Hetz C, Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov 5, 586–597, 2015. Chua FY, Adams BD. Androgen receptor and miR-206 regulation in prostate cancer. Transcription 8, 313–327, 2017. Cook N, Brais R, Qian W, Hak CC, Corrie PG. Endothelin-1 and endothelin B receptor expression in pancreatic adenocarcinoma. J Clin Pathol 68, 309–313, 2015. Dashwood MR, Loesch A. Endothelin-1 as a neuropeptide: neurotransmitter or neurovascular effects

Open access
Effect of glucose deprivation on the expression of genes encoding glucocorticoid receptor and some related factors in ERN1-knockdown U87 glioma cells

synchronized HeLa cells. Proc Natl Acad Sci USA 108, 21069–21074, 2011. Dasgupta S, Putluri N, Long W, Zhang B, Wang J, Kaushik AK, Arnold JM, Bhowmik SK, Stashi E, Brennan CA, Rajapakshe K, Coarfa C, Mitsiades N, Ittmann MM, Chinnaiyan AM, Sreekumar A, O’Malley BW. Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest 125, 1174–1188, 2015. de Guia RM, Herzig S. How do glucocorticoids regulate lipid metabolism? Adv Exp Med Biol 872, 127–144, 2015. Dejeans N, Barroso K, Fernandez-Zapico ME, Samali

Open access
The effects of Curcuma longa and curcumin on reproductive systems

. Th erapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47, 293-303, 2001. Eigner D, Scholz D. Ferula asa-foetida and Curcuma longa in traditional medical treatment and diet in Nepal. J Ethnopharmacol 67, 1-6, 1999. Farombi EO, Abarikwu SO, Adedara IA, Oyeyemi MO. Curcumin and kolaviron ameliorate di‐n‐butylphthalate‐induced testicular damage in rats. Basic Clin Pharmacol Toxicol 100

Open access
Metformin Impacts the Prognosis of Cancer Patients with Type 2 Diabetes

metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 22: 2640-2645, 2011. 28. Spratt DE, Zhang C, Zumsteg ZS, Pei X, Zhang Z, Zelefsky MJ. Metformin and prostate cancer: Reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 63: 709-716, 2013. 29. Kaushik D, Karnes RJ, Eisenberg MS, Rangel LJ, Carlson RE, Bergstralh EJ. Effect of metformin on prostate cancer outcomes after radical prostatectomy. Urol Oncol 32: 43.e41-47, 2014. 30. Romero IL

Open access
Low Total Testosterone-Component of Metabolic Syndrome

? Transl Androl Urol 5(6):898-908,2016 5. Lopez DS, Advani S, Tsilidis KK, Wang R, Canfield S. Endogenous and exogenous testosterone and prostate cancer: decreased, increased or null-risk? Transl Androl Urol . 6(3): 566-579, 2017 6. Bjorntorp P . Endocrine abnormalities in obesity. Diabetes Rev 5: 52-68, 1997 7. Laaksonen DE, Niskanen L, Punnonen K et al . Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27(5):1036-1041, 2004 8. Kolovou GD, Anagnostopoulou KK, Salpea

Open access
Study On The Prevalence Of Various Forms Of Cancer In Diabetic Patients Hospitalized In The National Institute Of Diabetes, Nutrition And Metabolic Diseases “Prof. N.C. Paulescu”

://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx and http://globocan.iarc.fr/Pages/fact_sheets_population.aspx 9. Rapp K, Schroeder J, Klenk J et al . Fasting blood glucose and cancer risk in a cohort of more than 140 000 adults in Austria. Diabetologia 49: 945–952, 2006. 10. Stattin P, Björ O, Ferrari P et al . Prospective study of hyperglycemia and cancer risk. Diabetes Care 30: 561–567, 2007. 11. Bonovas S, Filioussi K, Tsantes A . Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47: 1071–1078, 2004. 12. Joost HG. Diabetes and cancer: epidemiology and

Open access
The functions of circulating tumor cells in early diagnosis and surveillance during cancer advancement

first-, second-, or third-line therapy and measured CTCs using an immunomagnetic separation technique.[ 9 ] They found that patients with unfavorable compared with favorable baseline CTCs had shorter median PFS (4.5 months vs . 7.9 months; P = 0.0002) and OS (9.4 months vs . 18.5 months; P < 0.0001), showing that the number of CTCs before and during the treatment is an independent predictor of PFS and OS in patients with mCRC.[ 9 ] Application of CTCs in castration-resistant prostate cancer diagnosis To establish the relationship between posttreatment CTC

Open access